drugset / Trial / NCT02887625
Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea
Timeline
- Start
- 2015-02
- Primary completion
- 2017-05
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide | Peptide | 2 mg | Other |
| Subject | Pioglitazone | Small molecule | 30 mg | — |
| Comparator | insulin aspart | Protein / enzyme biologic | — | — |
| Comparator | insulin glargine | Protein / enzyme biologic | — | — |